MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 90 filers reported holding MARINUS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,118,378 | -23.8% | 138,929 | +2.9% | 0.00% | – |
| Q2 2023 | $1,466,806 | +986.3% | 135,065 | +590.2% | 0.00% | – |
| Q1 2023 | $135,026 | +37.6% | 19,569 | -20.6% | 0.00% | – |
| Q4 2022 | $98,147 | +14.1% | 24,660 | +92.5% | 0.00% | – |
| Q3 2022 | $86,000 | +38.7% | 12,809 | 0.0% | 0.00% | – |
| Q2 2022 | $62,000 | -93.0% | 12,809 | -86.5% | 0.00% | – |
| Q1 2022 | $889,000 | -19.4% | 95,047 | +2.5% | 0.00% | – |
| Q4 2021 | $1,103,000 | +4.5% | 92,766 | 0.0% | 0.00% | – |
| Q3 2021 | $1,056,000 | -35.4% | 92,766 | +1.9% | 0.00% | -100.0% |
| Q2 2021 | $1,634,000 | +41.0% | 91,045 | +21.7% | 0.00% | – |
| Q1 2021 | $1,159,000 | +54.5% | 74,832 | +21.8% | 0.00% | – |
| Q4 2020 | $750,000 | +1.5% | 61,420 | +6.9% | 0.00% | – |
| Q3 2020 | $739,000 | – | 57,466 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 2,145,337 | $17,269,963 | 7.70% |
| Bleichroeder LP | 1,872,463 | $15,073,327 | 3.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,204,942 | $41,899,783 | 2.26% |
| Opaleye Management Inc. | 584,000 | $4,701,200 | 1.53% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $11,520,017 | 1.29% |
| Cormorant Asset Management, LP | 2,625,000 | $21,131,250 | 1.23% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 290,000 | $2,337,400 | 0.79% |
| Ikarian Capital, LLC | 746,069 | $6,005,856 | 0.72% |
| Eventide Asset Management | 4,529,997 | $36,466,476 | 0.66% |
| Altium Capital Management LP | 125,033 | $1,006,516 | 0.52% |